Hilton Capital Management’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q2 | – | Sell |
-4,097
| Closed | -$212K | – | 134 |
|
|
2022
Q1 | $212K | Buy |
+4,097
| New | +$213K | 0.02% | 115 |
|
|
2021
Q3 | – | Sell |
-5,344
| Closed | -$209K | – | 144 |
|
|
2021
Q2 | $209K | Buy |
+5,344
| New | +$208K | 0.02% | 120 |
|
|
2020
Q4 | – | Sell |
-5,881
| Closed | -$205K | – | 120 |
|
|
2020
Q3 | $205K | Sell |
5,881
-435,363
| -99% | -$15.3M | 0.02% | 76 |
|
|
2020
Q2 | $13.7M | Buy |
+441,244
| New | +$15M | 1.71% | 22 |
|
|
2020
Q1 | – | Sell |
-5,640
| Closed | -$210K | – | 95 |
|
|
2019
Q4 | $210K | Buy |
5,640
+278
| +5% | +$9.9K | 0.03% | 101 |
|
|
2019
Q3 | $183K | Buy |
5,362
+998
| +23% | +$36.3K | 0.02% | 107 |
|
|
2019
Q2 | $179K | Hold |
4,364
| – | – | 0.02% | 113 |
|
|
2019
Q1 | $176K | Buy |
4,364
+102
| +2% | +$4.08K | 0.02% | 119 |
|
|
2018
Q4 | $177K | Buy |
4,262
+893
| +27% | +$37.1K | 0.03% | 118 |
|
|
2018
Q3 | $141K | Sell |
3,369
-21
| -0.6% | -$808 | 0.02% | 136 |
|
|
2018
Q2 | $117K | Buy |
+3,390
| New | +$116K | 0.02% | 160 |
|
|
2017
Q2 | – | Sell |
-19,382
| Closed | -$629K | – | 135 |
|
|
2017
Q1 | $629K | Buy |
+19,382
| New | +$611K | 0.12% | 63 |
|
|
2016
Q4 | – | Sell |
-40,092
| Closed | -$1.29M | – | 133 |
|
|
2016
Q3 | $1.29M | Buy |
+40,092
| New | +$1.34M | 0.32% | 45 |
|
|
2016
Q1 | – | Sell |
-246,438
| Closed | -$7.55M | – | 100 |
|
|
2015
Q4 | $7.55M | Buy |
246,438
+23,172
| +10% | +$729K | 2.43% | 15 |
|
|
2015
Q3 | $6.65M | Buy |
223,266
+14,942
| +7% | +$479K | 2.28% | 17 |
|
|
2015
Q2 | $6.63M | Buy |
208,324
+11,651
| +6% | +$380K | 1.87% | 22 |
|
|
2015
Q1 | $6.52M | Buy |
196,673
+38,709
| +25% | +$1.23M | 2.31% | 20 |
|
|
2014
Q4 | $4.67M | Buy |
157,964
+9,806
| +7% | +$281K | 1.52% | 28 |
|
|
2014
Q3 | $4.16M | Buy |
148,158
+13,912
| +10% | +$390K | 1.31% | 32 |
|
|
2014
Q2 | $3.78M | Buy |
134,246
+42,690
| +47% | +$1.22M | 1.23% | 32 |
|
|
2014
Q1 | $2.79M | Buy |
91,556
+13,091
| +17% | +$390K | 1.09% | 31 |
|
|
2013
Q4 | $2.28M | Buy |
78,465
+59,730
| +319% | +$1.74M | 0.88% | 34 |
|
|
2013
Q3 | $511K | Sell |
18,735
-6,782
| -27% | -$185K | 0.24% | 48 |
|
|
2013
Q2 | $678K | Buy |
+25,517
| New | +$705K | 0.33% | 40 |
|
Other funds holding PFE
Hilton Capital Management's PFE Position: Q2 2022 in Review
Hilton Capital Management sold out of Pfizer (PFE) in Q2 2022, closing a stake of 4,097 shares — an estimated $212K sold.
Hilton Capital Management first reported a position in PFE in Q2 2013 and held it in 24 quarters. The position peaked at $13.7M in Q2 2020. 3,158 funds tracked by Wall St. Rank hold PFE as of Q2 2022.
- Hilton Capital Management reported no remaining Pfizer position as of Q2 2022 after selling out during the quarter.
- Hilton Capital Management sold 4,097 Pfizer shares in Q2 2022, an estimated $212K.
- Hilton Capital Management first reported a position in Pfizer in Q2 2013 and held it in 24 quarters.
- Hilton Capital Management's Pfizer position peaked at $13.7M in Q2 2020.
- 3,158 funds tracked by Wall St. Rank held Pfizer as of Q2 2022.
Based on Hilton Capital Management's 13F filing for Q2 2022, filed 8 Aug 2022.